NovAccess Global Inc. (XSNX)
Operating as a biopharmaceutical firm, NovAccess Global Inc. focuses on developing innovative immunotherapies to treat individuals with brain tumors across the United States. Their primary expertise is in pioneering research that leverages a patient's own immune system to target and eliminate cancerous cells. The company, founded in 1997, has its headquarters situated in Chesterland, Ohio.
Sector: Biotechnology
Industry: Biotechnology
NovAccess Global Inc.
- 0.0%
- 439
- 31.36
Float 26.32M · FMP free float
The cost to borrow XSNX shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- 7
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 439 sh |
| Oct 15, 2026 | 439 sh |
| Sep 30, 2026 | 439 sh |
| Sep 15, 2026 | 439 sh |
| Aug 31, 2026 | 439 sh |
Latest fails to deliver
| Date | Shares failed |
|---|---|
| Oct 19, 2026 | 7 sh |
| Oct 1, 2026 | 3 sh |
| Sep 30, 2026 | 3 sh |
| Sep 29, 2026 | 3 sh |
| Sep 28, 2026 | 3 sh |
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
FINRA publishes no off-exchange short volume for this symbol.
FINRA's weekly alternative trading system (dark pool) volume for XSNX: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 439 XSNX shares were sold short (<0.01% of a 26.32M-share float, 31.36 days to cover).